S&P 500   3,349.16 (+0.64%)
DOW   27,386.98 (+0.68%)
QQQ   274.64 (+1.32%)
AAPL   455.61 (+3.49%)
MSFT   216.35 (+1.60%)
FB   265.28 (+6.49%)
GOOGL   1,504.95 (+1.75%)
AMZN   3,225.00 (+0.62%)
NVDA   453.42 (+0.43%)
CGC   17.52 (-8.80%)
BABA   265.68 (+0.29%)
TSLA   1,489.58 (+0.31%)
MU   48.70 (-4.60%)
GE   6.33 (-1.09%)
AMD   86.71 (+1.64%)
T   29.84 (-0.03%)
F   6.93 (-0.43%)
ACB   10.31 (-3.73%)
GILD   68.81 (-0.28%)
NFLX   509.08 (+1.39%)
DIS   130.82 (+2.52%)
BAC   25.47 (+0.32%)
BA   172.20 (-1.19%)
S&P 500   3,349.16 (+0.64%)
DOW   27,386.98 (+0.68%)
QQQ   274.64 (+1.32%)
AAPL   455.61 (+3.49%)
MSFT   216.35 (+1.60%)
FB   265.28 (+6.49%)
GOOGL   1,504.95 (+1.75%)
AMZN   3,225.00 (+0.62%)
NVDA   453.42 (+0.43%)
CGC   17.52 (-8.80%)
BABA   265.68 (+0.29%)
TSLA   1,489.58 (+0.31%)
MU   48.70 (-4.60%)
GE   6.33 (-1.09%)
AMD   86.71 (+1.64%)
T   29.84 (-0.03%)
F   6.93 (-0.43%)
ACB   10.31 (-3.73%)
GILD   68.81 (-0.28%)
NFLX   509.08 (+1.39%)
DIS   130.82 (+2.52%)
BAC   25.47 (+0.32%)
BA   172.20 (-1.19%)
S&P 500   3,349.16 (+0.64%)
DOW   27,386.98 (+0.68%)
QQQ   274.64 (+1.32%)
AAPL   455.61 (+3.49%)
MSFT   216.35 (+1.60%)
FB   265.28 (+6.49%)
GOOGL   1,504.95 (+1.75%)
AMZN   3,225.00 (+0.62%)
NVDA   453.42 (+0.43%)
CGC   17.52 (-8.80%)
BABA   265.68 (+0.29%)
TSLA   1,489.58 (+0.31%)
MU   48.70 (-4.60%)
GE   6.33 (-1.09%)
AMD   86.71 (+1.64%)
T   29.84 (-0.03%)
F   6.93 (-0.43%)
ACB   10.31 (-3.73%)
GILD   68.81 (-0.28%)
NFLX   509.08 (+1.39%)
DIS   130.82 (+2.52%)
BAC   25.47 (+0.32%)
BA   172.20 (-1.19%)
S&P 500   3,349.16 (+0.64%)
DOW   27,386.98 (+0.68%)
QQQ   274.64 (+1.32%)
AAPL   455.61 (+3.49%)
MSFT   216.35 (+1.60%)
FB   265.28 (+6.49%)
GOOGL   1,504.95 (+1.75%)
AMZN   3,225.00 (+0.62%)
NVDA   453.42 (+0.43%)
CGC   17.52 (-8.80%)
BABA   265.68 (+0.29%)
TSLA   1,489.58 (+0.31%)
MU   48.70 (-4.60%)
GE   6.33 (-1.09%)
AMD   86.71 (+1.64%)
T   29.84 (-0.03%)
F   6.93 (-0.43%)
ACB   10.31 (-3.73%)
GILD   68.81 (-0.28%)
NFLX   509.08 (+1.39%)
DIS   130.82 (+2.52%)
BAC   25.47 (+0.32%)
BA   172.20 (-1.19%)
Log in

NASDAQ:UBXUnity Biotechnology Stock Price, Forecast & News

$10.66
+0.15 (+1.43 %)
(As of 08/6/2020 04:00 PM ET)
Add
Compare
Today's Range
$10.35
Now: $10.66
$11.21
50-Day Range
$7.60
MA: $8.74
$10.23
52-Week Range
$4.62
Now: $10.66
$11.21
Volume857,982 shs
Average Volume293,077 shs
Market Capitalization$554.75 million
P/E RatioN/A
Dividend YieldN/A
Beta0.42
Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to extend human health span. The company's lead drug candidates include UBX0101 that is in Phase 1 clinical study for musculoskeletal disease; and UBX1967 for ophthalmologic diseases. It is also developing programs in pulmonary disorders. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was founded in 2009 and is headquartered in Brisbane, California.
Read More
Unity Biotechnology logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 2.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.75 out of 5 stars


Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:UBX
CUSIPN/A
WebN/A
PhoneN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees94
Market Cap$554.75 million
Next Earnings Date11/4/2020 (Estimated)
OptionableNot Optionable
$10.66
+0.15 (+1.43 %)
(As of 08/6/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive UBX News and Ratings via Email

Sign-up to receive the latest news and ratings for UBX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Unity Biotechnology (NASDAQ:UBX) Frequently Asked Questions

How has Unity Biotechnology's stock been impacted by COVID-19 (Coronavirus)?

Unity Biotechnology's stock was trading at $5.39 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, UBX stock has increased by 97.8% and is now trading at $10.66.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of Unity Biotechnology?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Unity Biotechnology in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Unity Biotechnology
.

When is Unity Biotechnology's next earnings date?

Unity Biotechnology is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for Unity Biotechnology
.

How were Unity Biotechnology's earnings last quarter?

Unity Biotechnology Inc (NASDAQ:UBX) posted its quarterly earnings results on Friday, July, 31st. The company reported ($0.38) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.51) by $0.13.
View Unity Biotechnology's earnings history
.

What price target have analysts set for UBX?

4 Wall Street analysts have issued 1-year price objectives for Unity Biotechnology's stock. Their forecasts range from $13.00 to $35.00. On average, they anticipate Unity Biotechnology's share price to reach $25.25 in the next year. This suggests a possible upside of 136.9% from the stock's current price.
View analysts' price targets for Unity Biotechnology
.

Has Unity Biotechnology been receiving favorable news coverage?

Press coverage about UBX stock has been trending very positive on Thursday, InfoTrie Sentiment Analysis reports. InfoTrie rates the sentiment of press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Unity Biotechnology earned a media sentiment score of 3.2 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 6.0 out of 10, meaning that recent press coverage is somewhat likely to have an effect on the company's share price in the next few days.
View the latest news about Unity Biotechnology
.

Are investors shorting Unity Biotechnology?

Unity Biotechnology saw a increase in short interest during the month of June. As of June 30th, there was short interest totaling 4,670,000 shares, an increase of 8.1% from the June 15th total of 4,320,000 shares. Based on an average trading volume of 288,500 shares, the short-interest ratio is currently 16.2 days. Currently, 18.6% of the shares of the stock are sold short.
View Unity Biotechnology's Current Options Chain
.

Who are some of Unity Biotechnology's key competitors?

What other stocks do shareholders of Unity Biotechnology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Unity Biotechnology investors own include Canopy Growth (CGC), NIO (NIO), Gilead Sciences (GILD), NVIDIA (NVDA), AbbVie (ABBV), Alibaba Group (BABA), Inovio Pharmaceuticals (INO), JD.Com (JD), Sorrento Therapeutics (SRNE) and Advanced Micro Devices (AMD).

Who are Unity Biotechnology's key executives?

Unity Biotechnology's management team includes the following people:
  • Dr. Nathaniel E. David, Co-Founder, Pres & Exec. Director (Age 52, Pay $640.86k)
  • Mr. Robert C. Goeltz II, Chief Financial Officer (Age 47, Pay $577.3k)
  • Dr. Anirvan Ghosh, Director & CEO (Age 56)
  • Dr. Jan M. van Deursen, Founder
  • Dr. Judith Campisi, Founder

When did Unity Biotechnology IPO?

(UBX) raised $85 million in an IPO on Thursday, May 3rd 2018. The company issued 5,000,000 shares at a price of $16.00-$18.00 per share. Goldman Sachs, Morgan Stanley and Citigroup served as the underwriters for the IPO and Mizuho Securities was co-manager.

What is Unity Biotechnology's stock symbol?

Unity Biotechnology trades on the NASDAQ under the ticker symbol "UBX."

Who are Unity Biotechnology's major shareholders?

Unity Biotechnology's stock is owned by many different institutional and retail investors. Top institutional investors include Russell Investments Group Ltd. (0.42%), Asymmetry Capital Management L.P. (0.23%), Bessemer Group Inc. (0.20%), Moloney Securities Asset Management LLC (0.04%), SG Americas Securities LLC (0.04%) and ProShare Advisors LLC (0.03%).

Which institutional investors are selling Unity Biotechnology stock?

UBX stock was sold by a variety of institutional investors in the last quarter, including Moloney Securities Asset Management LLC, UBS Group AG, Russell Investments Group Ltd., and Investors Financial Group LLC.

Which institutional investors are buying Unity Biotechnology stock?

UBX stock was bought by a variety of institutional investors in the last quarter, including Asymmetry Capital Management L.P., Bessemer Group Inc., SG Americas Securities LLC, and ProShare Advisors LLC.

How do I buy shares of Unity Biotechnology?

Shares of UBX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Unity Biotechnology's stock price today?

One share of UBX stock can currently be purchased for approximately $10.66.

How big of a company is Unity Biotechnology?

Unity Biotechnology has a market capitalization of $554.75 million. Unity Biotechnology employs 94 workers across the globe.

This page was last updated on 8/6/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.